Key result
Long noncoding RNAs regulate diabetic kidney disease pathogenesis and offer novel therapeutic targets.
Long noncoding RNAs play a regulatory role in diabetic kidney disease and may represent novel therapeutic targets.
Answers are grounded in this paper and cite their sources.
May warrant preclinical validation of lncRNA targets in diabetic kidney disease; leaves open clinical translation pending prospective trials.
Diabetic kidney disease is a progressive disorder that develops secondary to diabetes. Current strategies for the clinical management of the disease can delay its onset and prevent progression, yet a significant proportion of patients still develop renal failure. The need for more advanced pharmaceuticals is therefore critical for improved treatment strategies. Recent studies support a role for long noncoding RNAs (lncRNAs) in the pathogenesis of human disease. Here we review recent experimental results linking lncRNAs with diabetic kidney disease. A better understanding of the regulatory role that lncRNAs play in the development of diabetic kidney disease may lead to identification of novel targets for therapeutic intervention.
No takes yet. Share an insight, caveat, or question.
Leti et al. (2017) conducted a review in Diabetic kidney disease. Long noncoding RNAs (lncRNAs) was evaluated. Long noncoding RNAs play a regulatory role in the pathogenesis of diabetic kidney disease and may serve as novel targets for therapeutic intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: